Alliance for Building Better Medicine’s Post

At ICON, we recognize and celebrate the remarkable contributions of women who have been pioneers in clinical research and pharmaceutical advancements. In this blog, we highlight the achievements of two sets of extraordinary women who have left an indelible mark on the fields of STEM and healthcare. https://ow.ly/rgVY50QAA5b

BUILDING THE FUTURE, CELEBRATING THE PAST    This week marked a milestone for Pfizer in Finland, Iceland, Norway and Denmark. On 3rd and 4th of June, the first days of summer, we gathered in Copenhagen to mark the creation of our FIND-cluster.     However, 4th of June didn’t just mark that we could FINDally meet all of us in the same place. It also marked the 175th anniversary of Pfizer. This overlap provided a wonderful framework for our meeting and reminded us of the foundation we’re built on: The first bricks for this foundation was laid in Brooklyn back in 1849 by two cousins, Charles Pfizer and Charles Erhart. In 1924, Pfizer celebrated it’s 75th anniversary for its 306 employees. By 1939 Pfizer was recognized as a leader in fermentation technology, and in 1950, the first pharmaceutical product was sold under the Pfizer brand.     The rest is history. History that we are incredibly proud of. We’re proud to have been at the forefront of some of the most profound changes in medicine and technology, and we aren’t planning to rest on the laurels – we believe we are on the cusp of an era where technology and innovative therapies intersect like never before.   That’s why we are excited to press forward with a renewed focus on oncology and our ongoing dedication to finding new treatments and medications for myriad other diseases and conditions.     And that loops us right back to the present, and to our FIND-meeting in Copenhagen. Bringing everyone together was an important step in our efforts to realize the potential synergies that exist between our countries, our people and our goals. Further, it was an important step in establishing our FIND culture. And it was just great to finally meet in person and see new connections being made and friendships formed.   Now, FIND is all fueled up and ready to bring the next generation of breakthroughs to patients across Finland, Iceland, Norway and Denmark - for the next 175 years and beyond. #sciencewillwin #outdoyesterday #pfizerproud  

🎉 Highlighting Innovation at the 9th RSC-BMCS Fragment-based Drug Discovery Meeting! 🎉 We're thrilled to share that CHARM Therapeutics is playing a pivotal role at the 9th RSC-BMCS Fragment-based Drug Discovery meeting, taking place today and tomorrow! Geoffrey Smith from our Medicinal Chemistry team will be presenting our cutting-edge research through an engaging poster presentation. 🔍 This event is a cornerstone for those passionate about advancing fragment-based drug discovery. Our involvement underscores the innovative approaches and hard work our team dedicates to pushing the boundaries of what's possible in the field. 🌐 Geoffrey's presentation is not just about showcasing our latest findings; it's about fostering a community of collaboration, insight sharing, and professional growth. We're leveraging LinkedIn to connect with like-minded professionals and industry leaders, making every interaction count. 👏 Please join us in supporting Geoffrey and the CHARM Therapeutics team. Your engagement—likes, shares, and comments—will not only elevate our research but also strengthen the ties within our scientific community. Let's make #Fragments24 a memorable event by spreading the word and celebrating the innovations that drive us forward. #Fragments24 #RSCBMCS #FragmentBasedDrugDiscovery #CHARMTherapeutics #ScienceImpact #PosterPresentation #Networking

While the biotech industry has been facing a downturn the last couple of years, some big biotech names have been able to capitalize on their landmark products to launch new innovative projects. Faced with financial challenges, the leaders of the industry have been able to adapt to the changing dynamics of the market. At a time when the industry is set to recover, the companies in this list will play an important role in the developments of this year and beyond. Here are the fourteen biotech companies with a market capitalization above $100 billion.

The Sanofi culture continues to inspire me, even a decade later. It is a culture that arises out of a global community of employees driven by passion and purpose and a profound connection to the end result -- to offer medicines to patients in need of a solution. Having interviewed hundreds of Sanofi employees, I have been most inspired by the passion, purpose and strong level of commitment that I believe is born from a deep level of empathy. I offer more details in my 90 second video. #sanofistories #DiscoverExtraordinary #sanofi #corporateculture #greatcorporation #greatcorporateculture @BenJolliffe

The State of the Commonwealth is always a great kick off to a new year and look ahead. Among the various goals and priorities for 2024, Governor Healey highlighted the role of public transit and the continued support for the growth and development of the life sciences industry in MA. These two areas intersect deeply with us at Cambridge Crossing, where public transit has played a central role in connectivity and accessibility to the CX neighborhood and Kendall Square, and where industry leading companies have expanded the life science landscape by calling CX home including Sanofi, Philips, Bristol Myers Squibb, Cerevel Therapeutics and Astellas Pharma. As CX continues to grow, we look forward to supporting the Commonwealth's vision of growth and development. https://lnkd.in/eRNZkmzb

Publication of NIBRT’s Annual Report 2023 NIBRT today published its Annual Report for 2023 which highlights a 7% growth in revenue bringing research and training activity to the highest level in the Institute’s history. The success of the Irish biopharma industry is well documented, with biopharma firmly established as a key pillar of the Irish economy. There are 84,000 highly skilled people directly and indirectly employed in the sector and the expectation is that this will increase by up to 10,000 jobs over the next 5 years. 2023 saw continued strong performance of the sector with significant new developments including Astellas, Lilly, MSD, Novo Nordisk and others. NIBRT continued its strong support of the sector throughout 2023 with some of the key achievements in the year including: • A 7% growth in overall revenue, bringing research and training activity to the highest level in the Institute’s history. • 9% increase in training activity with client companies based in Ireland. • 28% growth in research activity, underpinned by the joint appointment of new Principal Investigators in partnership with Irish and international universities. • The signing of two new NIBRT global partnerships in the US. • The opening of the Advanced Therapies building and the CONCEPT facilities. Download and read full press release here -https://hubs.la/Q02j66Fd0

Click on the below link to download and read NIBRT National Institute for Bioprocessing Research and Training 2023 annual report. #lifeatnibrt #biopharma #research #training

Investors gathering in Melbourne for world-leading biotech investment event AusBioInvest 2023, Australia's premier biotech investment event, is drawing together local and international health investors, and happening next Monday, 30 October 2023 in Melbourne.   With only just over a week to go, now is your final chance to confirm your attendance. This full-day conference will provide you with a rare opportunity to hear from keynote and panel investor speakers, and 26 private and public companies spanning early to late-stage development, demonstrating the potential of Australia’s life sciences.   Qualified investors are invited to register for free, joining up to 250 delegates, including global pharmaceutical companies. >> https://lnkd.in/g2DWJfVq Company presentations have been scheduled in relation to their therapeutic area, and whether they are publicly listed or, private companies ensuring investors and brokers can make the most of their time and target the therapeutics they’re most interested in.   > Investors - qualified investors are eligible for complimentary registration. Apply for your pass now. > Interested delegates - Hear from our line-up of life science companies and network with CEOs, pharma executives and life science investors. A standard registration rate is available; register now.  #AusBioInv